Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells—a process in which p38 mitogen-activated protein kinase signaling has an important role

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 3, 2016, Pages 344-351

  Xia, Lin ^a,b   Dong, Zhaogang ^a   Zhang, Yun ^a   Zhang, Xiaoying ^a   Song, Xiaobin ^a   Sun, Mingxia ^a   Hu, Yingwei ^a   Liu, Shaohua ^a   Wang, Ketao ^a   Qu, Xun ^a   Wei, Fengcai ^a  

^a SHANDONG UNIVERSITY   (China)

^b The Baoshan Branch Institute of Shanghai Shuguang Hospital   (China)

Author keywords

angiogenesis; dendritic cell; granulocyte macrophage colony stimulating factor; interleukin 4; vascular endothelial growth factor receptor 1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTRACELLULAR SIGNALING; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; RAW 264.7 CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMIDAZOLES; INTERLEUKIN-4; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84905541916     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.06.008     Document Type: Article

References (41)

1. 1 Ferrara, N., Kerbel, R.S., Angiogenesis as a therapeutic target. Nature 438 (2005), 967–974.
2. 2 Wu, F.T., Stefanini, M.O., Mac Gabhann, F., Kontos, C.D., Annex, B.H., Popel, A.S., A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14 (2010), 528–552.
3. 3 Carmeliet, P., Angiogenesis in health and disease. Nat Med 9 (2003), 653–660.
4. 4 Roskoski, R. Jr., Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62 (2007), 179–213.
5. 5 Takahashi, H., Shibuya, M., The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109 (2005), 227–241.
6. 6 Maharaj, A.S., D'Amore, P.A., Roles for VEGF in the adult. Microvasc Res 74 (2007), 100–113.
7. 7 Olsson, A.K., Dimberg, A., Kreugerg, J., Claesson-Welsh, L., VEGF receptor signaling–in control of vascular function. Nat Rev Mol Cell Biol 7 (2006), 359–771.
8. 8 Ahmad, S., Ahmed, A., Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95 (2004), 884–891.
9. 9 Kendall, R.L., Wang, G., Thomas, K.A., Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996), 324–328.
10. 10 Bando, H., Weich, H.A., Brokelmann, M., Horiguchi, S., Funata, N., Ogawa, T., et al. Association between intra-tumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92 (2005), 553–561.
11. 11 Jaroszewicz, J., Januszkiewicz, M., Flisiak, R., Rogalska, M., Kalinowska, A., Wierzbicka, I., Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine 44 (2008), 14–17.
12. 12 Gehlbach, P., Demetriades, A.M., Yamamoto, S., Deering, T., Xiao, W.H., Duh, E.J., et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 14 (2003), 129–141.
13. 13 Kapsenberg, M.L., Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3 (2003), 984–993.
14. 14 Zhu, J., Paul, W.E., CD4 T cells: fates, functions, and faults. Blood 112 (2008), 1557–1569.
15. 15 D'Amore, P.A., Vascular endothelial cell growth factor-A: not just for endothelial cells anymore. Am J Pathol 171 (2007), 14–18.
16. 16 Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999), 9–22.
17. 17 Fernandez Pujol, B., Lucibello, F.C., Zuzarte, M., Lütjens, P., Müller, R., Havemann, K., Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 80 (2001), 99–110.
18. 18 Kim, Y.S., Choi, S.J., Tae, Y.M., Lee, B.J., Jeon, S.G., Oh, S.Y., et al. Distinct roles of vascular endothelial growth factor receptor-1- and receptor-2-mediated signaling in T cell priming and Th17 polarization to lipopolysaccharide-containing allergens in the lung. J Immunol 185 (2010), 5648–5655.
19. 19 Sugiyama, M., Kakeji, Y., Tsujitani, S., Harada, Y., Onimaru, M., Yoshida, K., et al. Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites. Mol Cancer Ther 10 (2011), 540–549.
20. 20 Coukos, G., Benencia, F., Buckanovich, R.J., Conejo-Garcia, J.R., The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 92 (2005), 143–154.
21. 21 Sozzani, S., Rusnati, M., Riboldi, E., Mitola, S., Presta, M., Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28 (2007), 385–392.
22. 22 Berger, T.G., Feuerstein, B., Strasser, E., Hirsch, U., Schreiner, D., Schuler, G., et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 268 (2002), 131–140.
23. 23 Saxena, R.K., Vallyathan, V., Lewis, D.M., Evidence for lipopolysaccharide-induced differentiation of RAW264.7 murine macrophage cell line into dendritic like cells. J Biosci 28 (2003), 129–134.
24. 24 Shen, L.H., Zhou, L., Wang, B.Y., Pu, J., Hu, L.H., Chai, D.J., et al. Oxidized low-density lipoprotein induces differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Atherosclerosis 199 (2008), 257–264.
25. 25 GuezGuez, A., Prod'homme, V., Mouska, X., Baudot, A., Blin-Wakkach, C., Rottapel, R., et al. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem 285 (2010), 20952–20963.
26. 26 Curiel, T.J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64 (2004), 5535–5538.
27. 27 Kishuku, M., Nishioka, Y., Abe, S., Kishi, J., Ogino, H., Aono, Y., et al. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J Immunol 183 (2009), 8176–8185.
28. 28 Eubank, T.D., Roberts, R., Galloway, M., Wang, Y., Cohn, D.E., Marsh, C.B., GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 21 (2004), 831–842.
29. 29 Cuadrado, A., Nebreda, A.R., Mechanisms and functions of p38 MAPK signaling. Biochem J 429 (2010), 403–417.
30. 30 Bulavin, D.V., Fornace, A.J. Jr., p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92 (2004), 95–118.
31. 31 Nebreda, A.R., Porras, A., p38 MAP kinases: beyond the stress response. Trends Biochem Sci 25 (2000), 257–260.
32. 32 Ono, K., Han, J., The p38 signal transduction pathway: activation and function. Cell Signal 12 (2000), 1–13.
33. 33 Ihn, H., Yamane, K., Asano, Y., Kubo, M., Tamaki, K., IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase de-pendent pathway. J Immunol 168 (2002), 1895–1902.
34. 34 Shao, Q., Ning, H., Lv, J., Liu, Y., Zhao, X., Ren, G., et al. Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells. Blood 119 (2012), 4636–4644.
35. 35 Terada, K., Kaziro, Y., Satoh, T., Ras-dependent activation of c-Jun N-terminal kinase/stress-activated protein kinase in response to interleukin-3 stimulation in hematopoietic BaF3 cells. J Biol Chem 272 (1997), 4544–4548.
36. 36 Nagata, Y., Nishida, E., Todokoro, K., Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood 89 (1997), 2664–2669.
37. 37 Wojchowski, D.M., He, T.C., Signal transduction in the erythropoietin receptor system. Stem Cells 11 (2001), 381–392.
38. 38 Henklova, P., Vrzal, R., Papouskova, B., Bednar, P., Jancova, P., Anzenbacherova, E., et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol 593 (2008), 16–23.
39. 39 Zatechka, S.D., Lou, M.F., Studies of the mitogen-activated protein kinases and phosphatidylinositol-3 kinase in the lens. Exp Eye Res 75 (2002), 177–192.
40. 40 Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D.P., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160 (1998), 1224–1232.
41. 41 Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996), 1096–1103.